Document Detail


Effect of propionyl-L-carnitine on experimental myocardial infarction in dogs.
MedLine Citation:
PMID:  2031876     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Limitation on infarct size, using propionyl-L-carnitine (Sigma-Tau) by itself and with the calcium entry blocker, tiapamil (Hoffmann-LaRoche), was evaluated in two groups of ten dogs each, during chronic (9 days) myocardial infarction. There were eight dogs that served as the control group. A closed-chest model was used to produce the thrombus by placing a helically shaped copper wire in the LAD by catheter technique, under x-ray visualization. Necrotic tissue in serial transventricular sections were delineated by triphenyltetrazolium chloride and measured by computer technique, using an IBM PC interfaced with a digitizing pad, 9 days following occlusion. The mean total amount of necrosis in the propionyl-L-carnitine (7.4%) and the propionyl-L-carnitine/tiapamil (6.7%) groups were significantly less (p less than .01) than found in the control (14.1%) group, reflecting a difference of 50 and 58%, respectively, between the treated groups and control. A number of significant between-group comparisons (p less than .05 to p less than .001), under the same conditions, were found for various ischemia, hemodynamic, and hematologic variables followed before and at 30, 60, 90, 120, and 180 minutes after occlusion, as well as on the second and ninth day. The results of this study strongly suggest that propionyl-L-carnitine and propionyl-L-carnitine with tiapamil has a protective effect on myocardial function, following thrombotic occlusion of the LAD, as well as limiting the resulting infarct size.
Authors:
J E Leasure; K Kordenat
Related Documents :
4458946 - Effects of dc electric countershock on ventricular function, cation balance and endogen...
22032706 - Eplerenone survival benefits in heart failure patients post-myocardial infarction are i...
21712526 - Potent long-term cardioprotective effects of single low-dose insulin-like growth factor...
3761566 - Myocardial ischemia stimulates catecholamine synthesis and catabolism in the dog adrena...
1378786 - The importance of stress-induced cardiac wall motion abnormalities in the evaluation of...
15012926 - Clinical trials update from the american heart association meeting: omega-3 fatty acids...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  5 Suppl 1     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  1991 Feb 
Date Detail:
Created Date:  1991-06-27     Completed Date:  1991-06-27     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  85-95     Citation Subset:  IM    
Affiliation:
Cox Heart Institute, Wright State University, School of Medicine, Dayton, OH 45429.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Calcium Channel Blockers / therapeutic use*
Carnitine / analogs & derivatives*,  therapeutic use
Creatine Kinase / blood
Dogs
Drug Evaluation, Preclinical
Female
Hemodynamics / drug effects
L-Lactate Dehydrogenase / blood
Male
Myocardial Infarction / drug therapy*
Propylamines / therapeutic use*
Chemical
Reg. No./Substance:
0/Calcium Channel Blockers; 0/Propylamines; 17298-37-2/propionylcarnitine; 541-15-1/Carnitine; 57010-31-8/dimeditiapramine; EC 1.1.1.27/L-Lactate Dehydrogenase; EC 2.7.3.2/Creatine Kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Protective effects of propionyl-L-carnitine during ischemia and reperfusion.
Next Document:  Effect of propionyl-L-carnitine on human endothelial cells.